<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896912444159</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896912444159</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Immunohistochemical and Fluorescence In Situ Hybridization Studies on Noninvasive and Invasive Extramammary Paget’s Disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hikita</surname><given-names>Tomonori</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912444159">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Ohtsuki</surname><given-names>Yuji</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff2-1066896912444159">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Maeda</surname><given-names>Toshiharu</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff3-1066896912444159">3</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Furihata</surname><given-names>Mutsuo</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912444159">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896912444159"><label>1</label>Kochi Medical School, Kochi University, Matsuyama, Kochi, Japan</aff>
<aff id="aff2-1066896912444159"><label>2</label>Matsuyama-Shimin Hospital, Matsuyama, Ehime, Japan</aff>
<aff id="aff3-1066896912444159"><label>3</label>Ehime Prefectural Central Hospital, Matsuyama, Ehime, Japan</aff>
<author-notes>
<corresp id="corresp1-1066896912444159">Yuji Ohtsuki, Division of Pathology, Matsuyama-Shimin Hospital, Matsuyama, Ehime 790-0067, Japan Email: <email>y.ohtsuki@matsuyama-shimin-hsp.or.jp</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>10</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>5</issue>
<fpage>441</fpage>
<lpage>448</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>To determine useful immunohistochemical markers for tumor cells in extramammary Paget’s disease (EMPD), immunohistochemical (IHC) examinations in 17 patients with EMPD, including 4 patients with dermal invasion, were performed. Among the antibodies examined, cytokeratin 7 (CK7) and CK19 were strongly positive for both intraepidermal and dermally invasive tumor cells in all patients. CAM5.2 and mucin 1 (MUC1) were also good markers. Although IHC examination revealed positive for HER-2 in 4 EMPD patients with dermal invasion, 4 out of 13 noninvasive patients were IHC negative. Fluorescence in situ hybridization (FISH) study revealed negative results for <italic>HER-2</italic> gene amplification in 8 IHC positive patients, including each 4 patients of both noninvasive and dermal invasive cases. Our results show that besides CK7, CK19 is another favorable marker of tumor cells of EMPD. Four patients with dermal invasion were strongly positive for HER-2, although negative results were obtained in the FISH study. Further investigations are required to confirm the results of the FISH study.</p>
</abstract>
<kwd-group>
<kwd>extramammary Paget’s disease</kwd>
<kwd>immunohistochemistry</kwd>
<kwd>fluorescence in situ hybridization (FISH)</kwd>
<kwd>CK19</kwd>
<kwd>HER-2</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896912444159" sec-type="intro">
<title>Introduction</title>
<p>Extramammary Paget’s disease (EMPD) mostly involves the genital regions or scrotum. Tumor cells mainly proliferate in the epidermis, but in some patients, aggressive tumor cells invade the dermis and metastasize to the lymph nodes and some show mucus production. It is difficult to determine the tumor margins of epidermal and dermal invasion in patients with EMPD by histological examination. Markers of EMPD cells, such as cytokeratins (CK),<sup><xref ref-type="bibr" rid="bibr1-1066896912444159">1</xref><xref ref-type="bibr" rid="bibr2-1066896912444159"/><xref ref-type="bibr" rid="bibr3-1066896912444159"/>-<xref ref-type="bibr" rid="bibr4-1066896912444159">4</xref></sup> carcinoembryonic antigen (CEA),<sup><xref ref-type="bibr" rid="bibr1-1066896912444159">1</xref>,<xref ref-type="bibr" rid="bibr2-1066896912444159">2</xref></sup> epithelial membrane antigen (EMA),<sup><xref ref-type="bibr" rid="bibr1-1066896912444159">1</xref>,<xref ref-type="bibr" rid="bibr2-1066896912444159">2</xref></sup> and mucin 1 (MUC1)<sup><xref ref-type="bibr" rid="bibr3-1066896912444159">3</xref>,<xref ref-type="bibr" rid="bibr5-1066896912444159">5</xref></sup> have been reported to determine intraepidermal and dermal invasion.<sup><xref ref-type="bibr" rid="bibr6-1066896912444159">6</xref><xref ref-type="bibr" rid="bibr7-1066896912444159"/><xref ref-type="bibr" rid="bibr8-1066896912444159"/><xref ref-type="bibr" rid="bibr9-1066896912444159"/><xref ref-type="bibr" rid="bibr10-1066896912444159"/><xref ref-type="bibr" rid="bibr11-1066896912444159"/><xref ref-type="bibr" rid="bibr12-1066896912444159"/>-<xref ref-type="bibr" rid="bibr13-1066896912444159">13</xref></sup> Identification of specific markers of tumor cells will be extremely useful in clinical practice.</p>
<p>Thus, to determine the expression of specific markers of tumor cells in EMPD, we performed immunohistochemical (IHC) examination of markers in 17 patients with noninvasive or those with dermal invasion of EMPD. Although tumor cells in the epidermis and the dermis were positive for cytokeratins, including CK7 and CAM5.2, MUC1, CEA, and EMA, we determined the expression of another cytokeratin antibody, CK19, which has been only reported to be positive for EMPD cells.<sup><xref ref-type="bibr" rid="bibr14-1066896912444159">14</xref></sup> Histopathological examination clearly demonstrated that in addition to the other antigens, CK19 was also a very useful marker of EMPD cells in the present study. HER-2 positivity has been reported in mammary Paget’s disease (PD) or EMPD.<sup><xref ref-type="bibr" rid="bibr15-1066896912444159">15</xref><xref ref-type="bibr" rid="bibr16-1066896912444159"/><xref ref-type="bibr" rid="bibr17-1066896912444159"/>-<xref ref-type="bibr" rid="bibr18-1066896912444159">18</xref></sup> Moreover, EMPD patients with dermal invasion are expected to show greater HER-2 positivity than those without invasion; however, we did not observe any statistical significance by χ<sup>2</sup> test in our study. Recently, HER-2 is considered as a useful antibody for targeted therapy.<sup><xref ref-type="bibr" rid="bibr19-1066896912444159">19</xref></sup> Although chromogenic in situ hybridization (CISH) revealed <italic>HER-2</italic> gene amplification,<sup><xref ref-type="bibr" rid="bibr20-1066896912444159">20</xref></sup> no data on <italic>HER-2</italic> amplification obtained by fluorescence in situ hybridization (FISH) have been reported thus far. Therefore, we also performed FISH study using specimens immunohistochemically positive for HER-2 obtained from EMPD patients without invasion and those with dermal invasion.</p>
</sec>
<sec id="section2-1066896912444159" sec-type="materials|methods">
<title>Materials and Methods</title>
<p>We compared 4 patients with dermally invasive EMPD and 13 patients with noninvasive EMPD. We examined 17 patients (7 men and 10 women,) with ages ranging from 57 to 87 years (<xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>). The site of EMPD was the genital region in the case of 14 patients and the scrotum in the case of 3 patients (<xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>). The tumor was fixed in a 10% phosphate-buffered formalin solution and then most of the tumor was dissected into several slices, each of which was embedded in paraffin in a usual manner.</p>
<table-wrap id="table1-1066896912444159" position="float">
<label>Table 1.</label>
<caption><p>Immunohistochemical Characterization of Both Intraepidermal and/or Dermal Tumor Cells in Noninvasive or Invasive Extramammary Paget’s Disease</p></caption>
<graphic alternate-form-of="table1-1066896912444159" xlink:href="10.1177_1066896912444159-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Age</th>
<th align="center">Gender</th>
<th align="center">Location</th>
<th align="center">CK7</th>
<th align="center">CK19</th>
<th align="center">CK20</th>
<th align="center">CAM5.2</th>
<th align="center">CEA</th>
<th align="center">EMA</th>
<th align="center">MUC1</th>
<th align="center">Cyclin D1</th>
<th align="center"><xref ref-type="table-fn" rid="table-fn1-1066896912444159">*</xref>HER-2/FISH</th>
</tr>
</thead>
<tbody>
<tr>
<td colspan="12">Intraepidermal tumor cells in patients without invasion</td>
</tr>
<tr>
<td>79</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>79</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>c+</td>
<td>1+</td>
</tr>
<tr>
<td>63</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>c+</td>
<td>1+</td>
</tr>
<tr>
<td>76</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>(+)</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>70</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>(+)</td>
<td>−</td>
<td>+</td>
<td>n(+)</td>
<td>1+/1.2</td>
</tr>
<tr>
<td>66</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>(+)</td>
<td>(+)</td>
<td>+</td>
<td>−</td>
<td>1+/1.1</td>
</tr>
<tr>
<td>84</td>
<td>M</td>
<td>Scrotal</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>63</td>
<td>M</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>59</td>
<td>M</td>
<td>Scrotal</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>−</td>
</tr>
<tr>
<td>87</td>
<td>M</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>c<sup><xref ref-type="table-fn" rid="table-fn1-1066896912444159">+</xref></sup></td>
<td>2+/1.2</td>
</tr>
<tr>
<td>57</td>
<td>M</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>c<sup><xref ref-type="table-fn" rid="table-fn1-1066896912444159">+</xref></sup></td>
<td>1+/1.5</td>
</tr>
<tr>
<td>63</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>(+)</td>
<td>(+)</td>
<td>(+)</td>
<td>n(+)</td>
<td>1+</td>
</tr>
<tr>
<td>63</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>(+)</td>
<td>(+)</td>
<td>(+)</td>
<td>n(+)</td>
<td>1+/1.1</td>
</tr>
<tr>
<td colspan="12">Epidermal tumor cells in patients with invasion</td>
</tr>
<tr>
<td>85</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>(+)</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>c<sup><xref ref-type="table-fn" rid="table-fn1-1066896912444159">+</xref></sup></td>
<td>1+/1.2</td>
</tr>
<tr>
<td>63</td>
<td>M</td>
<td>Scrotal</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>(+)</td>
<td>+</td>
<td>n(+), c<sup><xref ref-type="table-fn" rid="table-fn1-1066896912444159">+</xref></sup></td>
<td>2+/1.1</td>
</tr>
<tr>
<td>66</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>(+)</td>
<td>+</td>
<td>+</td>
<td>(+)</td>
<td>+</td>
<td>−</td>
<td>1+/1.3</td>
</tr>
<tr>
<td>75</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>1+</td>
</tr>
<tr>
<td colspan="12">Dermal tumors cells in patients with invasion</td>
</tr>
<tr>
<td>85</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>c<sup><xref ref-type="table-fn" rid="table-fn1-1066896912444159">+</xref></sup></td>
<td>1+</td>
</tr>
<tr>
<td>63</td>
<td>M</td>
<td>Scrotal</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>n(+), c<sup><xref ref-type="table-fn" rid="table-fn1-1066896912444159">+</xref></sup></td>
<td>2+</td>
</tr>
<tr>
<td>66</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>(+)</td>
<td>+</td>
<td>+</td>
<td>(+)</td>
<td>+</td>
<td>−</td>
<td>1+</td>
</tr>
<tr>
<td>75</td>
<td>F</td>
<td>Genital</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>−</td>
<td>1+</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896912444159">
<p>Abbreviations: F, female; M, male; +, positive; (+), focal positive; −, negative; n(+), focal nuclear positivity; c+, cytoplasmic positivity; *HER-2/FISH: HER-2 immunohistochemistry/fluorescence in situ hybridization titer.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The dewaxed 4-µm sections were stained with hematoxylin–eosin (H&amp;E). For mucin staining, diastase-digested periodic acid-Schiff (DPAS) reaction was also performed in some patients. IHC examination of representative sections definitely containing tumor cells was performed for detailed investigation. IHC staining was performed as reported<sup><xref ref-type="bibr" rid="bibr21-1066896912444159">21</xref>,<xref ref-type="bibr" rid="bibr22-1066896912444159">22</xref></sup> by using the labeled streptavidin–biotin (LSAB) 2 kit/horseradish peroxidase (HRP; Dako, Kyoto, Japan) with diaminobenzidine as the substrate for HRP and using antibodies as listed in <xref ref-type="table" rid="table2-1066896912444159">Table 2</xref>.</p>
<table-wrap id="table2-1066896912444159" position="float">
<label>Table 2.</label>
<caption><p>Antibodies Used</p></caption>
<graphic alternate-form-of="table2-1066896912444159" xlink:href="10.1177_1066896912444159-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Antibody</th>
<th align="center">Dilution</th>
<th align="center">Pretreatment</th>
<th align="center">Manufacturer</th>
</tr>
</thead>
<tbody>
<tr>
<td>CK7</td>
<td>1:50</td>
<td>P</td>
<td>Dako</td>
</tr>
<tr>
<td>CK19</td>
<td>1:30</td>
<td>AC</td>
<td>Scytek</td>
</tr>
<tr>
<td>CK20</td>
<td>1:25</td>
<td>AC</td>
<td>Dako</td>
</tr>
<tr>
<td>CAM5.2</td>
<td>1:20</td>
<td>P</td>
<td>Becton–Dickinson</td>
</tr>
<tr>
<td>EMA</td>
<td>1:50</td>
<td>MW</td>
<td>Dako</td>
</tr>
<tr>
<td>CEA</td>
<td>1:25</td>
<td>P</td>
<td>Dako</td>
</tr>
<tr>
<td>MUC1</td>
<td>1:100</td>
<td>AC</td>
<td>BD Biosciences Pharmingen</td>
</tr>
<tr>
<td>HER-2</td>
<td>1:200</td>
<td>MW</td>
<td>Dako</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>1:50</td>
<td>AC</td>
<td>Dako</td>
</tr>
<tr>
<td>ER</td>
<td>1:50</td>
<td>AC</td>
<td>Dako</td>
</tr>
<tr>
<td>PGR</td>
<td>1:800</td>
<td>AC</td>
<td>Dako</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn2-1066896912444159">
<p>Abbreviations: EMA, epithelial membrane antigen; CEA, carcinoembryonic antigen; HER2, HER-2/neu; ER, estrogen receptor; PGR, progesterone receptor; P, pronase; AC, autoclaving; MW, microwave.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>FISH study was performed according to the procedure described in the manual of PathVysion HER-2 DNA probe kit (Abbott Molecular Inc, Japan), which was used for the examination of <italic>HER-2</italic> gene amplification in breast cancer.</p>
<p>Briefly, in each denatured DNA sample of tumor cells on deparaffinized sections, HER-2 DNA probe was hybridized with CEP 17 DNA probe. Then, after nuclear staining with 4′,6-diamidino-2-phenyl indole, positive HER-2 DNA (orange) and CEP17 DNA (green), were counted and analyzed under fluorescent microscope using MetaCyte scanning image cytometer (MetaSystems, Altlussheim, Germany). When orange signals were more than twice that of the green ones, the results of FISH were considered to be positive for amplification of <italic>HER-2</italic> gene. If the orange signals were less than twice that of the green ones, the results were considered to be negative.</p>
<p>Statistical study on HER-2 expression with IHC was done using χ<sup>2</sup> test, between EMPD patients without (13 cases) or with (4 cases) dermal invasion as shown in <xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>.</p>
<p>All patients participating in the present study have provided written informed consent, and the identities of each patient have been strictly protected.</p>
</sec>
<sec id="section3-1066896912444159" sec-type="results">
<title>Results</title>
<p>CK7, CK19, CAM5.2, and MUC1 were strongly positive antibodies for both intraepidermal and dermal invasion of tumor cells in all patients of 13/13 (100%) noninvasive and 4/4 (100%) dermal-invasive cases as shown in <xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>. However, detailed examination revealed that CK7 and CK19 were uniformly positive for all of tumor cells, including cells with dermal invasion (<xref ref-type="fig" rid="fig1-1066896912444159">Figure 1</xref>). CK7- and CK19-positive cells showed distinct tumor margins in the epidermis and clearly revealed dermal invasion (<xref ref-type="fig" rid="fig2-1066896912444159">Figure 2</xref>). On the other hand, CAM5.2 and MUC1 stained tumor cells very well, but stable staining of individual tumor cells in each patient was not possible. In some CAM5.2- and MUC1-positive patients, negative or weakly positive tumor cells were intermingled with the positive ones. CK20 was mostly negative although focally weak positive findings were found in only 2 patients (<xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>).</p>
<fig id="fig1-1066896912444159" position="float">
<label>Figure 1.</label>
<caption>
<p>(A) Intraepidermal tumor cell proliferation, including hair follicle (magnification 10×). Serial sections stained by (B) hematoxylin–eosin (H&amp;E; magnification 20×), (C) cytokeratin 7 (CK7; magnification 20×), and (D) CK19 (magnification 20×). Tumor cells were well stained in (C) and (D).</p>
</caption>
<graphic xlink:href="10.1177_1066896912444159-fig1.tif"/>
</fig>
<fig id="fig2-1066896912444159" position="float">
<label>Figure 2.</label>
<caption>
<p>(A) Cytokeratin 19 (CK19) sharply stained the margin of intraepidermal tumor cell growth and (B) dermal invasion was clearly shown with CK19 stain. Magnification: A and B 200×</p>
</caption>
<graphic xlink:href="10.1177_1066896912444159-fig2.tif"/>
</fig>
<p>Tumor cells were positively stained for EMA and CEA, but some patients were negative for these antigens. EMA was positive in 7/13 (50%) patients without invasion and 4/4 (100%) patients with dermal invasion; CEA was positive in 9/13 (66.6%) patients and 2/4 (50%) patients without invasion and with dermal invasion, respectively. In addition, the stainability of these antigens was not stable even in the case of patients positive for these antigens (<xref ref-type="fig" rid="fig3-1066896912444159">Figure 3</xref>). Cyclin D1 was positive only in a limited number of patients; a small number of nuclei were positive in 3/13 patients without invasion and 1/4 patients with dermal invasion. Estrogen receptor (ER) and progesterone receptor (PGR) were negative in 6 patients examined, including 4 patients without invasion and 2 with dermal invasion.</p>
<fig id="fig3-1066896912444159" position="float">
<label>Figure 3.</label>
<caption>
<p>Uneven staining of intraepidermal tumors cells with (A) epithelial membrane antigen (EMA) and (B) carcinoembryonic antigen (CEA) stains. Note intermingled negative and/or positive cells (A and B; magnification 200×)</p>
</caption>
<graphic xlink:href="10.1177_1066896912444159-fig3.tif"/>
</fig>
<p>HER-2 was positive in 8/13 (61.5%) patients without invasion and in all of 4 patients (100%) with dermal invasion. The tumor cell membranes were positive in linear fashion, including dermally invasive tumor cells (<xref ref-type="fig" rid="fig4-1066896912444159">Figure 4</xref>). Although we did not observe any statistically significant differences between HER-2 positivity in patients with and without dermal invasion according to χ<sup>2</sup> test (<italic>P</italic> &gt; .05), it is of interest that all patients with dermal invasion were positive for HER-2, which is consistent with the findings of IHC examination. FISH study showed negative results for HER-2 antibody in 8 patients, including those without and with dermal invasion, who were immunohistochemically positive for HER-2 (<xref ref-type="table" rid="table2-1066896912444159">Table 2</xref>). The FISH titers were from 1.1 to 1.5 (<xref ref-type="fig" rid="fig5-1066896912444159">Figure 5</xref>), and none of 8 patients showed a FISH titer of more than 2 points (<xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>).</p>
<fig id="fig4-1066896912444159" position="float">
<label>Figure 4.</label>
<caption>
<p>(A) 1+-positive and (B) 2+-positive intraepidermal tumor cells with HER-2 are shown in contrast with 2+dermally invasive tumor cells (C, D). Note positive immune reaction of tumor cell membranes. A-D: HER-2 stain; A, B, and D magnification 400× and C magnification 100×</p>
</caption>
<graphic xlink:href="10.1177_1066896912444159-fig4.tif"/>
</fig>
<fig id="fig5-1066896912444159" position="float">
<label>Figure 5.</label>
<caption>
<p>(A) 1+- and (C)2+- HER-2 positive patients were both negative with fluorescence in situ hybridization (FISH) study, as shown in B and D. Each was 1.1 and 1.5, respectively in titer. A and C: HER-2 stain, magnification 400×</p>
</caption>
<graphic xlink:href="10.1177_1066896912444159-fig5.tif"/>
</fig>
</sec>
<sec id="section4-1066896912444159" sec-type="discussion">
<title>Discussion</title>
<p>Our study showed that CK7 and CK19 were the excellent markers and CAM5.2 and MUC1 were the good markers of EMPD cells. Our results also indicate that CK7 and CK19 are extremely useful to clearly identify the margin of EMPD cells. Each tumor specimen obtained from all the 17 EMPD patients examined was distinctly positive for CK19 and CK7. However, although CAM5.2 and MUC1 were good markers,<sup><xref ref-type="bibr" rid="bibr3-1066896912444159">3</xref>,<xref ref-type="bibr" rid="bibr5-1066896912444159">5</xref></sup> they were not consistently expressed in individual cancer cells. Detailed observation revealed that in the large foci of cancer cells, positive and negative tumor cells were intermingled. Thus, CK19 and CK7 were more useful than CAM5.2 and MUC1. CK7 is a good marker of tumor cells in EMPD,<sup><xref ref-type="bibr" rid="bibr3-1066896912444159">3</xref></sup> but CK19 has not been reported as the marker of EMPD, except for one study.<sup><xref ref-type="bibr" rid="bibr14-1066896912444159">14</xref></sup> We have definitely confirmed that CK19 is an excellent marker of EMPD. Thus, CK19 and CK7 uniformly stained the cancer cells, and both these cytokeratins may be useful to determine the tumor margins of EMPD in clinical practice.</p>
<p>EMA and CEA also stain cancer cells, and they are reported to be good markers of EMPD,<sup><xref ref-type="bibr" rid="bibr1-1066896912444159">1</xref>,<xref ref-type="bibr" rid="bibr2-1066896912444159">2</xref></sup> but in our study, approximately 80% of the patients without invasion and those with invasion were positive for these antigens. The patients who were negative for these antigens have been described in <xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>.</p>
<p>Recently, cyclin D1 has also been reported to be a useful marker for the EMPD cells.<sup><xref ref-type="bibr" rid="bibr11-1066896912444159">11</xref>,<xref ref-type="bibr" rid="bibr12-1066896912444159">12</xref></sup> However, our results showed that only a few nuclei of cancer cells in 5 patients were positive for this antibody. Thus, on the basis of our results, cyclin D1 does not appear to be an excellent marker. Moreover, the cytoplasm of some cancer cells was stained with this antibody (<xref ref-type="table" rid="table1-1066896912444159">Table 1</xref>).</p>
<p>Comparison of the origin of EMPD with that of PD indicated that intraepidermal ductal cells of the sweat glands were the site of origin of PD because of the positivity of GCDFP-15<sup><xref ref-type="bibr" rid="bibr8-1066896912444159">8</xref></sup> and MFGM gp70<sup><xref ref-type="bibr" rid="bibr13-1066896912444159">13</xref></sup> but not of MFGM gp155,<sup><xref ref-type="bibr" rid="bibr13-1066896912444159">13</xref></sup> which was positive for intraductal cells of the mammary glands. Therefore, gp155 was positive in tumor cells of PD.<sup><xref ref-type="bibr" rid="bibr13-1066896912444159">13</xref></sup> ER and PGR were negative for EMPD,<sup><xref ref-type="bibr" rid="bibr3-1066896912444159">3</xref></sup> but positive for PD.<sup><xref ref-type="bibr" rid="bibr3-1066896912444159">3</xref></sup> These results indicated that PD cells were derived from ductal cells of the mammary gland. Consistent with the above findings, ER and PGR were negative in 6 EMPD patients, including those with dermal invasion. Thus, the origins of PD and EMPD appeared to be different.</p>
<p>In the present study, we could not obtain the statistical differences on HER-2 positivity with IHC between noninvasive and invasive cases of EMPD. To obtain more accurate statistical difference, we need to accumulate more samples, especially of dermal invasive cases of EMPD.</p>
<p>Immune therapy using HER-2 antibody was considered to be useful because of its success in breast cancer.<sup><xref ref-type="bibr" rid="bibr23-1066896912444159">23</xref>,<xref ref-type="bibr" rid="bibr24-1066896912444159">24</xref></sup> Some studies have reported<sup><xref ref-type="bibr" rid="bibr15-1066896912444159">15</xref><xref ref-type="bibr" rid="bibr16-1066896912444159"/><xref ref-type="bibr" rid="bibr17-1066896912444159"/><xref ref-type="bibr" rid="bibr18-1066896912444159"/><xref ref-type="bibr" rid="bibr19-1066896912444159"/>-<xref ref-type="bibr" rid="bibr20-1066896912444159">20</xref></sup> strong expression of HER-2 by immunohistochemical examination.<sup><xref ref-type="bibr" rid="bibr15-1066896912444159">15</xref><xref ref-type="bibr" rid="bibr16-1066896912444159"/><xref ref-type="bibr" rid="bibr17-1066896912444159"/><xref ref-type="bibr" rid="bibr18-1066896912444159"/>-<xref ref-type="bibr" rid="bibr19-1066896912444159">19</xref></sup> More than 40% Japanese EMPD patients, including those with aggressive invasive or metastatic tumors, were positive for HER-2.<sup><xref ref-type="bibr" rid="bibr18-1066896912444159">18</xref></sup> Although some patients are negative for intraepidermal cancer cells,<sup><xref ref-type="bibr" rid="bibr16-1066896912444159">16</xref></sup> our study showed that 8 out of 13 patients without invasion and all patients with dermal invasion were positive for intraepidermal cancer cells, including IHC2+ according to the standard of breast cancer.</p>
<p>Although CISH showed positive results of <italic>HER-2</italic> gene amplification,<sup><xref ref-type="bibr" rid="bibr20-1066896912444159">20</xref></sup> FISH study on EMPD has not been performed. In the present study, FISH showed that all the 8 patients, including those without invasion or those with dermal invasion were negative for <italic>HER-2</italic> although they were definitely immunohistochemically positive for HER-2 on the membranes of cancer cells. Their positivity was IHC1+ to IHC2+ according to the standard of breast cancer. The interrelationship between IHC examination and FISH for breast cancer showed that IHC3+ patients were mostly positive with FISH; however, there were several exceptions in some patients. IHC 2+ cases contained FISH-negative cases between 25% and 48% according to the reports of breast cancer.<sup><xref ref-type="bibr" rid="bibr23-1066896912444159">23</xref><xref ref-type="bibr" rid="bibr24-1066896912444159"/>-<xref ref-type="bibr" rid="bibr25-1066896912444159">25</xref></sup> Thus, it remains to be clarified whether <italic>HER-2</italic> was truly amplified in our IHC1+ to IHC2+ patients with EMPD, which were negative for HER-2 by FISH. If <italic>HER-2</italic> is amplified, it might be useful for targeted therapy of EMPD as suggested in recent studies.<sup><xref ref-type="bibr" rid="bibr19-1066896912444159">19</xref></sup></p>
<p>Our results indicate that in addition to CK7, CK19 is an excellent marker of tumor cells in EMPD, and all patients with dermal invasion were positive for HER-2, although no <italic>HER-2</italic> gene amplification was obtained in FISH study in these patients.</p>
<p>Further studies are required on additional number of patients, especially for <italic>HER-2</italic> gene amplification, to determine whether targeted therapy using HER-2 can be performed for EMPD in the near future.</p>
</sec>
</body>
<back>
<ack><p>The authors are grateful for the technical assistance of Mr S. Manabe, Ms K. Yamaoka, Mr Y. Okada, Mrs M. Izumimoto, Mrs Y. Matsuka, and Ms W. Tanihata, and for the secretarial assistance of Ms T. Kadota and Ms K. Takasuka.</p></ack>
<fn-group>
<fn fn-type="conflict">
<label>Declaration of Conflicting Interests</label>
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896912444159">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ordonetz</surname><given-names>NG</given-names></name>
<name><surname>Awalt</surname><given-names>H</given-names></name>
<name><surname>Mackay</surname><given-names>B</given-names></name>
</person-group>. <article-title>Mammary and extramammary Paget’s disease: an immunocytochemical and ultrastructural study</article-title>. <source>Cancer</source>. <year>1987</year>;<volume>59</volume>:<fpage>1173</fpage>-<lpage>1183</lpage>.</citation>
</ref>
<ref id="bibr2-1066896912444159">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ganjei</surname><given-names>P</given-names></name>
<name><surname>Giraldo</surname><given-names>KA</given-names></name>
<name><surname>Lampe</surname><given-names>B</given-names></name>
<name><surname>Nadji</surname><given-names>M</given-names></name>
</person-group>. <article-title>Vulvar Paget’s disease. Is immunohistochemistry helpful in assessing the surgical margins?</article-title> <source>J Reprod Med</source>. <year>1990</year>;<volume>35</volume>:<fpage>1002</fpage>-<lpage>1005</lpage>.</citation>
</ref>
<ref id="bibr3-1066896912444159">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Liegl</surname><given-names>B</given-names></name>
<name><surname>Leibl</surname><given-names>S</given-names></name>
<name><surname>Gogg-Kamerer</surname><given-names>M</given-names></name>
<name><surname>Tessaro</surname><given-names>B</given-names></name>
<name><surname>Horn</surname><given-names>LC</given-names></name>
<name><surname>Moinfar</surname><given-names>F</given-names></name>
</person-group>. <article-title>Mammary and extramammary Paget’s disease: an immunohistochemical study of 83 cases</article-title>. <source>Histopathology</source>. <year>2007</year>;<volume>50</volume>:<fpage>439</fpage>-<lpage>447</lpage>.</citation>
</ref>
<ref id="bibr4-1066896912444159">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thway</surname><given-names>K</given-names></name>
<name><surname>Polson</surname><given-names>A</given-names></name>
<name><surname>Pope</surname><given-names>R</given-names></name>
<name><surname>Thomas</surname><given-names>JM</given-names></name>
<name><surname>Fisher</surname><given-names>C</given-names></name>
</person-group>. <article-title>Extramammary Paget disease in a retrorectal dermoid cyst: report of a unique case</article-title>. <source>Am J Surg Pathol</source>. <year>2008</year>;<volume>32</volume>:<fpage>635</fpage>-<lpage>639</lpage>.</citation>
</ref>
<ref id="bibr5-1066896912444159">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yoshii</surname><given-names>N</given-names></name>
<name><surname>Yonezawa</surname><given-names>S</given-names></name>
<name><surname>Matsukita</surname><given-names>S</given-names></name>
<name><surname>Matsukita</surname><given-names>S</given-names></name>
<name><surname>Setoyama</surname><given-names>M</given-names></name>
<name><surname>Kanzaki</surname><given-names>T</given-names></name>
</person-group>. <article-title>Expression of mucin core proteins in extramammary Paget’s disease</article-title>. <source>Pathol Int</source>. <year>2002</year>;<volume>52</volume>:<fpage>390</fpage>-<lpage>399</lpage>.</citation>
</ref>
<ref id="bibr6-1066896912444159">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mori</surname><given-names>O</given-names></name>
<name><surname>Hachisuka</surname><given-names>H</given-names></name>
<name><surname>Nakano</surname><given-names>S</given-names></name>
<name><surname>Sasai</surname><given-names>Y</given-names></name>
<name><surname>Shiku</surname><given-names>H</given-names></name>
</person-group>. <article-title>Expression of ras p21 in mammary and extramammary Paget’s disease</article-title>. <source>Arch Pathol Lab Med</source>. <year>1990</year>;<volume>114</volume>:<fpage>858</fpage>-<lpage>861</lpage>.</citation>
</ref>
<ref id="bibr7-1066896912444159">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nakamura</surname><given-names>G</given-names></name>
<name><surname>Shikata</surname><given-names>N</given-names></name>
<name><surname>Shoji</surname><given-names>T</given-names></name>
<name><surname>Hatano</surname><given-names>T</given-names></name>
<name><surname>Hioki</surname><given-names>K</given-names></name>
<name><surname>Tsubura</surname><given-names>A</given-names></name>
</person-group>. <article-title>Immunohistochemical study of mammary and extramammary Paget’s disease</article-title>. <source>Anticancer Res</source>. <year>1995</year>;<volume>15</volume>:<fpage>467</fpage>-<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr8-1066896912444159">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yanai</surname><given-names>H</given-names></name>
<name><surname>Takahashi</surname><given-names>N</given-names></name>
<name><surname>Omori</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Immunohistochemistry of p63 in primary and secondary vulvar Paget’s disease</article-title>. <source>Pathol Int</source>. <year>2008</year>;<volume>58</volume>:<fpage>648</fpage>-<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr9-1066896912444159">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>S</given-names></name>
<name><surname>Moroi</surname><given-names>Y</given-names></name>
<name><surname>Urabe</surname><given-names>K</given-names></name>
<etal/>
</person-group>. <article-title>Differential expression of two new members of the p53 family, p63 and p73, in extramammary Paget’s disease</article-title>. <source>Clin Exp Dermatol</source>. <year>2008</year>;<volume>33</volume>:<fpage>634</fpage>-<lpage>640</lpage>.</citation>
</ref>
<ref id="bibr10-1066896912444159">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Xie</surname><given-names>LN</given-names></name>
<name><surname>Hayashide</surname><given-names>S</given-names></name>
<name><surname>Kido</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Stromal CD10 expression is correlated with invasiveness and proliferation of extramammary Paget disease</article-title>. <source>Br J Dermatol</source>. <year>2008</year>;<volume>158</volume>:<fpage>1389</fpage>-<lpage>1391</lpage>.</citation>
</ref>
<ref id="bibr11-1066896912444159">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aoyagi</surname><given-names>S</given-names></name>
<name><surname>Akiyama</surname><given-names>M</given-names></name>
<name><surname>Shimizu</surname><given-names>H</given-names></name>
</person-group>. <article-title>High expression of Ki-67 and cyclin D1 in invasive extramammary Paget’s disease</article-title>. <source>J Dermatol Sci</source>. <year>2008</year>;<volume>50</volume>:<fpage>177</fpage>-<lpage>184</lpage>.</citation>
</ref>
<ref id="bibr12-1066896912444159">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ellis</surname><given-names>PE</given-names></name>
<name><surname>Maclean</surname><given-names>AB</given-names></name>
<name><surname>Crow</surname><given-names>JC</given-names></name>
<name><surname>Wong</surname><given-names>Te</given-names></name>
<name><surname>Fong</surname><given-names>LF</given-names></name>
<name><surname>Rolfe</surname><given-names>KJ</given-names></name>
<name><surname>Perrett</surname><given-names>CW</given-names></name>
</person-group>. <article-title>Expression of cyclin D1 and retinoblastoma protein in Paget’s disease of the vulva and breast: an immunohistochemical study of 108 cases</article-title>. <source>Histopathology</source>. <year>2009</year>;<volume>55</volume>:<fpage>709</fpage>-<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr13-1066896912444159">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Imam</surname><given-names>A</given-names></name>
<name><surname>Yoshida</surname><given-names>SO</given-names></name>
<name><surname>Taylor</surname><given-names>CR</given-names></name>
</person-group>. <article-title>Distinguishing tumour cells of mammary from extramammary Paget’s disease using antibodies to two different glycoproteins from human milk-fat-globule membrane</article-title>. <source>Br J Cancer</source>. <year>1988</year>;<volume>58</volume>:<fpage>373</fpage>-<lpage>378</lpage>.</citation>
</ref>
<ref id="bibr14-1066896912444159">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Regauer</surname><given-names>S</given-names></name>
</person-group>. <article-title>Extramammary Paget’s disease—a proliferation of adnexal origin?</article-title> <source>Histopathology</source>. <year>2006</year>;<volume>48</volume>:<fpage>723</fpage>-<lpage>729</lpage>.</citation>
</ref>
<ref id="bibr15-1066896912444159">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Keatings</surname><given-names>L</given-names></name>
<name><surname>Sinclair</surname><given-names>J</given-names></name>
<name><surname>Wright</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>c-erbB-2 oncoprotein expression in mammary and extramammary Paget’s disease: an immunohistochemical study</article-title>. <source>Histopathology</source>. <year>1990</year>;<volume>17</volume>:<fpage>243</fpage>-<lpage>247</lpage>.</citation>
</ref>
<ref id="bibr16-1066896912444159">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nishi</surname><given-names>M</given-names></name>
<name><surname>Yoshida</surname><given-names>H</given-names></name>
<name><surname>Setoyama</surname><given-names>M</given-names></name>
<name><surname>Tashiro</surname><given-names>M</given-names></name>
</person-group>. <article-title>Immunohistochemical study of c-erbB-2 oncoprotein expression in extramammary Paget’s disease</article-title>. <source>Dermatology</source>. <year>1994</year>;<volume>188</volume>:<fpage>100</fpage>-<lpage>102</lpage>.</citation>
</ref>
<ref id="bibr17-1066896912444159">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Takata</surname><given-names>M</given-names></name>
<name><surname>Fujimoto</surname><given-names>A</given-names></name>
<name><surname>Aoki</surname><given-names>H</given-names></name>
<name><surname>Hatta</surname><given-names>N</given-names></name>
<name><surname>Ooi</surname><given-names>A</given-names></name>
<name><surname>Takehara</surname><given-names>K</given-names></name>
</person-group>. <article-title>erbB-2 overexpression but no activation of beta-Catenin gene in extramammary Paget’s disease</article-title>. <source>J Invest Dermatol</source>. <year>1999</year>;<volume>113</volume>:<fpage>258</fpage>-<lpage>262</lpage>.</citation>
</ref>
<ref id="bibr18-1066896912444159">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Plaza</surname><given-names>JA</given-names></name>
<name><surname>Torres-Cabala</surname><given-names>C</given-names></name>
<name><surname>Ivan</surname><given-names>D</given-names></name>
<name><surname>Prieto</surname><given-names>VG</given-names></name>
</person-group>. <article-title>HER-2/neu expression in extramammary Paget disease: a clinicopathologic and immunohistochemistry study of 47 cases with and without underlying malignancy</article-title>. <source>J Cutan Pathol</source>. <year>2009</year>;<volume>36</volume>:<fpage>729</fpage>-<lpage>733</lpage>.</citation>
</ref>
<ref id="bibr19-1066896912444159">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ogawa</surname><given-names>T</given-names></name>
<name><surname>Nagashima</surname><given-names>Y</given-names></name>
<name><surname>Wada</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Extramammary Paget’s disease: analysis of growth signal pathway from the human epidermal growth factor receptor 2 protein</article-title>. <source>Hum Pathol</source>. <year>2005</year>;<volume>36</volume>:<fpage>1273</fpage>-<lpage>1280</lpage>.</citation>
</ref>
<ref id="bibr20-1066896912444159">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanskanen</surname><given-names>M</given-names></name>
<name><surname>Jahkola</surname><given-names>T</given-names></name>
<name><surname>Asko-Seljavaara</surname><given-names>S</given-names></name>
<name><surname>Jalkanen</surname><given-names>J</given-names></name>
<name><surname>Isola</surname><given-names>J</given-names></name>
</person-group>. <article-title>HER2 oncogene amplification in extramammary Paget’s disease</article-title>. <source>Histopathology</source>. <year>2003</year>;<volume>42</volume>:<fpage>575</fpage>-<lpage>579</lpage>.</citation>
</ref>
<ref id="bibr21-1066896912444159">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohtsuki</surname><given-names>Y</given-names></name>
<name><surname>Fujita</surname><given-names>J</given-names></name>
<name><surname>Hachisuka</surname><given-names>Y</given-names></name>
<etal/>
</person-group>. <article-title>Immunohistochemical and immunoelectron microscopic studies of the localization of KL-6 and epithelial membrane antigen (EMA) in presumably normal pulmonary tissue and interstitial pneumonia</article-title>. <source>Med Mol Morphol</source>. <year>2007</year>;<volume>40</volume>:<fpage>198</fpage>-<lpage>202</lpage>.</citation>
</ref>
<ref id="bibr22-1066896912444159">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ohtsuki</surname><given-names>Y</given-names></name>
<name><surname>Nakanishi</surname><given-names>N</given-names></name>
<name><surname>Fujita</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Immunohistochemical distribution of SP-D, compared with those of SP-A and KL-6 in interstitial pneumonias</article-title>. <source>Med Mol Morphol</source>. <year>2007</year>;<volume>40</volume>:<fpage>163</fpage>-<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr23-1066896912444159">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tsuda</surname><given-names>H</given-names></name>
<name><surname>Akiyama</surname><given-names>F</given-names></name>
<name><surname>Terasaki</surname><given-names>H</given-names></name>
<etal/>
</person-group>. <article-title>Detection of HER-2/neu(c-erb B-2)DNA amplification in primary breast carcinoma. Interobserver reproducibility and correlation with immunohistochemical HER-2 overexpression</article-title>. <source>Cancer</source>. <year>2001</year>;<volume>92</volume>:<fpage>2965</fpage>-<lpage>2974</lpage>.</citation>
</ref>
<ref id="bibr24-1066896912444159">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dowsett</surname><given-names>M</given-names></name>
<name><surname>Bartlett</surname><given-names>J</given-names></name>
<name><surname>Ellis</surname><given-names>IO</given-names></name>
<etal/>
</person-group>. <article-title>Correlation between immunohistochemistry (HercepTest) and fluorescence in situ hybridization (FISH) for HER-2 in 426 breast carcinomas from 32 centres</article-title>. <source>J Pathol</source>. <year>2003</year>;<volume>199</volume>:<fpage>418</fpage>-<lpage>423</lpage>.</citation>
</ref>
<ref id="bibr25-1066896912444159">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Press</surname><given-names>MF</given-names></name>
<name><surname>Sauter</surname><given-names>G</given-names></name>
<name><surname>Bernstein</surname><given-names>L</given-names></name>
<etal/>
</person-group>. <article-title>Diagnostic elevation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials</article-title>. <source>Clin Cancer Res</source>. <year>2005</year>;<volume>11</volume>:<fpage>6598</fpage>-<lpage>6607</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>